# GE Vernova Inc.: financial statements, quarterly

GEV · NYSE · CIK 1996810 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/gev.md) · [Financials](/companies/gev/financials.md) · [Filings](/companies/gev/filings.md) · [Insiders](/companies/gev/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/gev/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [10.0 d](/filings/0001996810-26-000015.md) | [7.3](/filings/0001996810-25-000073.md) | [8.2](/filings/0001996810-25-000133.md) | [8.9](/filings/0001996810-25-000160.md) | [10.6 d](/filings/0001996810-26-000015.md) | [8.0](/filings/0001996810-26-000064.md) | [9.1](/filings/0001996810-26-000148.md) | [10.0](/filings/0001996810-26-000163.md) | [11.0 d](/filings/0001996810-26-000015.md) | [9.3](/filings/0001996810-26-000064.md) | [11.1](/filings/0001996810-26-000148.md) | [12.6](/filings/0001996810-26-000163.md) |
| Cost of revenue | $bn | [8.3 d](/filings/0001996810-26-000015.md) | [6.1](/filings/0001996810-25-000073.md) | [6.5](/filings/0001996810-25-000133.md) | [7.8](/filings/0001996810-25-000160.md) | [8.4 d](/filings/0001996810-26-000015.md) | [6.6](/filings/0001996810-26-000064.md) | [7.3](/filings/0001996810-26-000148.md) | [8.1](/filings/0001996810-26-000163.md) | [8.6 d](/filings/0001996810-26-000015.md) | [7.6](/filings/0001996810-26-000064.md) | [8.7](/filings/0001996810-26-000148.md) | [9.5](/filings/0001996810-26-000163.md) |
| Gross profit | $bn | [1.7 d](/filings/0001996810-26-000015.md) | [1.2](/filings/0001996810-25-000073.md) | [1.7](/filings/0001996810-25-000133.md) | [1.1](/filings/0001996810-25-000160.md) | [2.1 d](/filings/0001996810-26-000015.md) | [1.5](/filings/0001996810-26-000064.md) | [1.8](/filings/0001996810-26-000148.md) | [1.9](/filings/0001996810-26-000163.md) | [2.3 d](/filings/0001996810-26-000015.md) | [1.8](/filings/0001996810-26-000064.md) | [2.4](/filings/0001996810-26-000148.md) | [3.1](/filings/0001996810-26-000163.md) |
| Research and development | $bn | [0.3 d](/filings/0001996810-26-000015.md) | [0.2](/filings/0001996810-25-000073.md) | [0.2](/filings/0001996810-25-000133.md) | [0.2](/filings/0001996810-25-000160.md) | [0.3 d](/filings/0001996810-26-000015.md) | [0.2](/filings/0001996810-26-000064.md) | [0.3](/filings/0001996810-26-000148.md) | [0.3](/filings/0001996810-26-000163.md) | [0.4 d](/filings/0001996810-26-000015.md) | [0.3](/filings/0001996810-26-000064.md) | [0.3](/filings/0001996810-26-000148.md) | [0.4](/filings/0001996810-26-000163.md) |
| Selling, general and administrative | $bn | [1.3 d](/filings/0001996810-26-000015.md) | [1.2](/filings/0001996810-25-000073.md) | [0.9](/filings/0001996810-25-000133.md) | [1.2](/filings/0001996810-25-000160.md) | [1.3 d](/filings/0001996810-26-000015.md) | [1.2](/filings/0001996810-26-000064.md) | [1.2](/filings/0001996810-26-000148.md) | [1.2](/filings/0001996810-26-000163.md) | [1.4 d](/filings/0001996810-26-000015.md) | [1.3](/filings/0001996810-26-000064.md) | [1.4](/filings/0001996810-26-000148.md) | [1.4](/filings/0001996810-26-000163.md) |
| Operating income | $bn | [0.2 d](/filings/0001996810-26-000015.md) | [(0.3)](/filings/0001996810-25-000073.md) | [0.5](/filings/0001996810-25-000133.md) | [(0.4)](/filings/0001996810-25-000160.md) | [0.6 d](/filings/0001996810-26-000015.md) | [0.0](/filings/0001996810-26-000064.md) | [0.4](/filings/0001996810-26-000148.md) | [0.4](/filings/0001996810-26-000163.md) | [0.6 d](/filings/0001996810-26-000015.md) | [0.2](/filings/0001996810-26-000064.md) | [0.7](/filings/0001996810-26-000148.md) | [1.4](/filings/0001996810-26-000163.md) |
| Income tax | $bn | [0.1 d](/filings/0001996810-26-000015.md) | [0.0](/filings/0001996810-25-000073.md) | [0.3](/filings/0001996810-25-000133.md) | [(0.0)](/filings/0001996810-25-000160.md) | [0.6 d](/filings/0001996810-26-000015.md) | [0.1](/filings/0001996810-26-000064.md) | [0.2](/filings/0001996810-26-000148.md) | [0.3](/filings/0001996810-26-000163.md) | [(2.6) d](/filings/0001996810-26-000015.md) | [0.4](/filings/0001996810-26-000064.md) | [0.3](/filings/0001996810-26-000148.md) | [0.5](/filings/0001996810-26-000163.md) |
| Net income | $bn | [0.2 d](/filings/0001996810-26-000015.md) | [(0.1)](/filings/0001996810-25-000073.md) | [1.3](/filings/0001996810-25-000133.md) | [(0.1)](/filings/0001996810-25-000160.md) | [0.5 d](/filings/0001996810-26-000015.md) | [0.3](/filings/0001996810-26-000064.md) | [0.5](/filings/0001996810-26-000148.md) | [0.5](/filings/0001996810-26-000163.md) | [3.7 d](/filings/0001996810-26-000015.md) | [4.7](/filings/0001996810-26-000064.md) | [0.7](/filings/0001996810-26-000148.md) | [1.3](/filings/0001996810-26-000163.md) |
| Diluted EPS | $ per share | not reported | [(0.47)](/filings/0001996810-25-000073.md) | [4.65](/filings/0001996810-25-000133.md) | [(0.35)](/filings/0001996810-25-000160.md) | not reported | [0.91](/filings/0001996810-26-000064.md) | [1.86](/filings/0001996810-26-000148.md) | [1.64](/filings/0001996810-26-000163.md) | not reported | [17.44](/filings/0001996810-26-000064.md) | [2.47](/filings/0001996810-26-000148.md) | [4.81](/filings/0001996810-26-000163.md) |
| Basic EPS | $ per share | not reported | [(0.47)](/filings/0001996810-25-000073.md) | [4.72](/filings/0001996810-25-000133.md) | [(0.35)](/filings/0001996810-25-000160.md) | not reported | [0.92](/filings/0001996810-26-000064.md) | [1.89](/filings/0001996810-26-000148.md) | [1.66](/filings/0001996810-26-000163.md) | not reported | [17.65](/filings/0001996810-26-000064.md) | [2.49](/filings/0001996810-26-000148.md) | [4.86](/filings/0001996810-26-000163.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Current assets | $bn | [27.4](/filings/0001996810-25-000011.md) | [29.2](/filings/0001996810-24-000008.md) | [30.7](/filings/0001996810-24-000067.md) | [33.1](/filings/0001996810-24-000083.md) | [34.2](/filings/0001996810-26-000015.md) | [33.9](/filings/0001996810-25-000073.md) | [34.7](/filings/0001996810-25-000133.md) | [36.3](/filings/0001996810-25-000160.md) | [40.2](/filings/0001996810-26-000163.md) | [43.0](/filings/0001996810-26-000064.md) | [47.4](/filings/0001996810-26-000148.md) | [51.7](/filings/0001996810-26-000163.md) |
| Total assets | $bn | [46.1](/filings/0001996810-25-000011.md) | [47.9](/filings/0001996810-24-000008.md) | [48.1](/filings/0001996810-24-000067.md) | [50.9](/filings/0001996810-24-000083.md) | [51.5](/filings/0001996810-26-000015.md) | [51.6](/filings/0001996810-25-000073.md) | [53.1](/filings/0001996810-25-000133.md) | [54.4](/filings/0001996810-25-000160.md) | [63.0](/filings/0001996810-26-000163.md) | [75.6](/filings/0001996810-26-000064.md) | [80.8](/filings/0001996810-26-000148.md) | [86.2](/filings/0001996810-26-000163.md) |
| Current liabilities | $bn | [29.3](/filings/0001996810-25-000011.md) | [29.5](/filings/0001996810-24-000008.md) | [29.1](/filings/0001996810-24-000067.md) | [31.2](/filings/0001996810-24-000083.md) | [31.7](/filings/0001996810-26-000015.md) | [32.7](/filings/0001996810-25-000073.md) | [33.8](/filings/0001996810-25-000133.md) | [35.3](/filings/0001996810-25-000160.md) | [41.0](/filings/0001996810-26-000163.md) | [48.1](/filings/0001996810-26-000064.md) | [55.8](/filings/0001996810-26-000148.md) | [62.5](/filings/0001996810-26-000163.md) |
| Total liabilities | $bn | [37.7](/filings/0001996810-25-000011.md) | [37.9](/filings/0001996810-24-000008.md) | [38.0](/filings/0001996810-24-000067.md) | [40.3](/filings/0001996810-24-000083.md) | [40.9](/filings/0001996810-26-000015.md) | [41.9](/filings/0001996810-25-000073.md) | [43.1](/filings/0001996810-25-000133.md) | [44.7](/filings/0001996810-25-000160.md) | [50.7](/filings/0001996810-26-000163.md) | [60.5](/filings/0001996810-26-000064.md) | [67.7](/filings/0001996810-26-000148.md) | [73.7](/filings/0001996810-26-000163.md) |
| Short-term borrowings | $bn | [0.1](/filings/0001996810-25-000011.md) | not reported | not reported | not reported | [0.1](/filings/0001996810-26-000015.md) | not reported | not reported | not reported | [0.1](/filings/0001996810-26-000015.md) | not reported | not reported | not reported |
| Shareholders' equity | $bn | [7.4](/filings/0001996810-25-000011.md) | [9.0](/filings/0001996810-24-000008.md) | [9.1](/filings/0001996810-24-000067.md) | [9.5](/filings/0001996810-24-000083.md) | [9.5](/filings/0001996810-26-000015.md) | [8.6](/filings/0001996810-25-000073.md) | [8.9](/filings/0001996810-25-000133.md) | [8.6](/filings/0001996810-25-000160.md) | [11.2](/filings/0001996810-26-000163.md) | [13.9](/filings/0001996810-26-000064.md) | [12.0](/filings/0001996810-26-000148.md) | [11.4](/filings/0001996810-26-000163.md) |

- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [1,931 d](/filings/0001996810-26-000015.md) | [(444)](/filings/0001996810-25-000073.md) | [979 d](/filings/0001996810-25-000133.md) | [1,127 d](/filings/0001996810-25-000160.md) | [921 d](/filings/0001996810-26-000015.md) | [1,161](/filings/0001996810-26-000064.md) | [367 d](/filings/0001996810-26-000148.md) | [980 d](/filings/0001996810-26-000163.md) | [2,479 d](/filings/0001996810-26-000015.md) | [5,188](/filings/0001996810-26-000064.md) | [5,492 d](/filings/0001996810-26-000148.md) | [6,057 d](/filings/0001996810-26-000163.md) |
| Capital expenditure | $m | [280 d](/filings/0001996810-26-000015.md) | [217](/filings/0001996810-25-000073.md) | [157 d](/filings/0001996810-25-000133.md) | [159 d](/filings/0001996810-25-000160.md) | [350 d](/filings/0001996810-26-000015.md) | [186](/filings/0001996810-26-000064.md) | [173 d](/filings/0001996810-26-000148.md) | [247 d](/filings/0001996810-26-000163.md) | [671 d](/filings/0001996810-26-000015.md) | [397](/filings/0001996810-26-000064.md) | [386 d](/filings/0001996810-26-000148.md) | [647 d](/filings/0001996810-26-000163.md) |
| Dividends paid | $m | not reported | [0.0](/filings/0001996810-25-000073.md) | [0.0 d](/filings/0001996810-25-000133.md) | [0.0 d](/filings/0001996810-25-000160.md) | [0.0 d](/filings/0001996810-26-000015.md) | [69.0](/filings/0001996810-26-000064.md) | [70.0 d](/filings/0001996810-26-000148.md) | [68.0 d](/filings/0001996810-26-000163.md) | [68.0 d](/filings/0001996810-26-000015.md) | [137](/filings/0001996810-26-000064.md) | [136 d](/filings/0001996810-26-000148.md) | [133 d](/filings/0001996810-26-000163.md) |
| Share repurchases | $m | not reported | [0.0](/filings/0001996810-25-000073.md) | [0.0 d](/filings/0001996810-25-000133.md) | [40.0 d](/filings/0001996810-25-000160.md) | [3.0 d](/filings/0001996810-26-000015.md) | [1,101](/filings/0001996810-26-000064.md) | [480 d](/filings/0001996810-26-000148.md) | [660 d](/filings/0001996810-26-000163.md) | [1,075 d](/filings/0001996810-26-000015.md) | [1,278](/filings/0001996810-26-000064.md) | [2,393 d](/filings/0001996810-26-000148.md) | [1,625 d](/filings/0001996810-26-000163.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | period not labelled (2023-06-30) | period not labelled (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [274](/filings/0001996810-24-000067.md) | [274](/filings/0001996810-24-000083.md) | [274](/filings/0001996810-25-000073.md) | [278](/filings/0001996810-25-000133.md) | [275](/filings/0001996810-25-000160.md) | [279](/filings/0001996810-26-000064.md) | [276](/filings/0001996810-26-000148.md) | [275](/filings/0001996810-26-000163.md) | [272](/filings/0001996810-26-000064.md) | [270](/filings/0001996810-26-000148.md) | [268](/filings/0001996810-26-000163.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 264,677,066 at 2026-09-30, from the cover of the [10-Q filed 2026-10-28](/filings/0001996810-26-000163.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 28, 2026, 07:27 ET. No prices; not investment advice.